A Phase 2 Study of PTX 100 in Patients With Relapsed/Refractory CTCL
Prescient Therapeutics, Ltd.
Prescient Therapeutics, Ltd.
Memorial Sloan Kettering Cancer Center
City of Hope Medical Center
SciTech Development, Inc.
Barbara Ann Karmanos Cancer Institute
Stanford University